Fracture reducing potential of hormone replacement therapy on a population level

Maturitas

Volumn 54, Issue 3, 2006, Pages 285-293

  Vestergaard, Peter ^a   Rejnmark, Lars ^a   Mosekilde, Leif ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Epidemiology; Fracture; Hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; CYPROTERONE; DIENOGEST; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRIOL; LEVONORGESTREL; MEDROXYPROGESTERONE; PROGESTERONE; TIBOLONE; TRIMEGESTONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; COLLES FRACTURE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DENMARK; FEMALE; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; RISK ASSESSMENT; RISK REDUCTION; SOCIOECONOMICS; SPINE FRACTURE;

CASE-CONTROL STUDIES; DENMARK; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; REGISTRIES; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 33747425523     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.12.004     Document Type: Article

References (25)

1. Torgerson D.J., and Bell-Syer S.E.M. hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285 (2001) 2891-2897
2. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-33.
3. Torgerson D.J., and Bell-Syer S.E.M. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2 (2001) 7-10
4. Wells G., Tugwell P., Shea B., et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 3 (2002) 529-539
5. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 91 (2004) 1701-1712
6. Mosekilde L., Beck-Nielsen H., Sørensen O.H., et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women-results of the Danish Osteoporosis Prevention Study. Maturitas 36 (2000) 181-193
7. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
8. Hulley S., Furberg C., Barret-Connor E., et al. Estrogen/progestin Replacement Study follow-up (HERS II): noncardiovascular disease outcomes during 6-8 years or hormone therapy. JAMA 280 (2002) 605-613
9. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative Randomized Trial. JAMA 290 (2003) 1729-1738
10. Mosekilde L., Vestergaard P., Andresen J., et al. Effects of 10 years of estradiol on fracture risk and other outcomes in early postmenopausal women-the Danish Osteoporosis Prevention Study. Calcif Tissue Int 74 (2004) S38 [Abstract]
11. Humphrey L.L., Chan B.K., and Sox H.C. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137 (2002) 273-284
12. Frank L. Epidemiology. When an entire country is a cohort. Science 287 (2000) 2398-2399
13. Andersen T.F., Madsen M., Jørgensen J., Mellemkjær L., and Olsen J.H. The Danish National Hospital Register. Dan Med Bull 46 (1999) 263-268
14. Vestergaard P., and Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 156 (2002) l-10
15. Wacholder S., McLaughlin J.K., Silverman D.T., and Mandel J.S. Selection of controls in case-control studies. Part I: principles. Am J Epidemiol 135 (1992) 1019-1028
16. Capella D. Descriptive tools and analysis. In: Dukes MNG, editor. Drug utilization studies: methods and uses. Copenhagen: WHO Regional Publications, European Series No. 45; 1993. p. 5-78.
17. Nielsen G.L., Sørensen H.T., Zhou W., Steffensen F.H., and Olsen J. The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med 10 (1997) 203-205
18. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40 (1987) 373-383
19. de Groot V., Beckerman H., Lankhorst G.J., and Bouter L.M. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 56 (2003) 221-229
20. Miettinen O.S. Theoretical epidemiology: principles of occurrence research in medicine (1985), Wiley & Sons, New York p. 1-359
21. Vestergaard P., Mollerup C.L., Frøkjær V.G., Christiansen P., Blichert-Toft M., and Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321 (2000) 598-602
22. Vestergaard P., Hermann A.P., Gram J., et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 28 (1997) 137-145
23. Stadberg E., Mattsson L.A., and Uvebrant M. 17 Beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 23 (1996) 31-39
24. Baerug U., Winge T., Nordland G., et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms?. Climacteric 1 (1998) 219-228
25. Hoidrup S., Grønbæk M., Gottschau A., Lauritzen J.B., and Schroll M. Alcohol intake, beverage preference, and risk of hip fracture in men and women. Am J Epidemiol 149 (1999) 993-1001